NWRN Share Price Performance
CHF 0
-6.64 (-100.00%)
Price CHF 0
Fair ValueCHF 73.63
Share Pricen/a
Newron Pharmaceuticals S.p.A. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 42 Fair Values set on narratives written by author
NWRN Community Narratives
AN
Fair Value CHF 73.63 77.0% undervalued intrinsic discount
Late Stage Schizophrenia Pipeline And Extended Patents Will Transform Long Term Prospects
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Late Stage Schizophrenia Pipeline And Extended Patents Will Transform Long Term Prospects
Catalysts About Newron Pharmaceuticals Newron Pharmaceuticals is a biopharmaceutical company focused on developing evenamide as an add-on therapy for schizophrenia and related central nervous system disorders. What are the underlying business or industry changes driving this perspective?Read more
6
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
CHF 73.63
77.0% undervalued intrinsic discount
Fair Value
Profit Margin
49.31%
Future PE
30x
Price in 2029
CHF 87.4
Trending Discussion
Recently Updated Narratives
AN
Late Stage Schizophrenia Pipeline And Extended Patents Will Transform Long Term Prospects
Fair Value: CHF 73.63 77.0% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Newron Pharmaceuticals S.p.A. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Sep 22, 2026
- -0.64
- 100.00%
- -69.22%
- -336.4%
About NWRN
- Founded
- 1999
- Employees
- 27
- CEO
- WebsiteView website
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company’s lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. It has a strategic partnership with Zambon and Meiji Seika Pharma Co., Ltd. for the commercialization of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.
